UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 169

Sortiert nach

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

The lancet oncology, 2017, Vol.18 (1), p.88-99

2017

Volltextzugriff (PDF)

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Leukemia, 2022-05, Vol.36 (5), p.1408-1411

2022

Volltextzugriff (PDF)

Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia

Cardiovascular toxicology, 2021-03, Vol.21 (3), p.236-247

2021

Volltextzugriff (PDF)

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

Annals of hematology, 2018-09, Vol.97 (9), p.1591-1600

2018

Volltextzugriff (PDF)

Fix low dose venetoclax‐azacitidine treatment of unfit acute myeloid leukemia patients

European journal of haematology, 2024-08, Vol.113 (2), p.183-189

2024

Volltextzugriff (PDF)

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

Haematologica (Roma), 2024-02, Vol.109 (2), p.676

2024

Volltextzugriff (PDF)

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Haematologica (Roma), 2014-07, Vol.99 (7), p.1184

2014

Volltextzugriff (PDF)

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

International journal of hematology, 2019-11, Vol.110 (5), p.559-565

2019

Volltextzugriff (PDF)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis

Haematologica (Roma), 2023-07, Vol.108 (7), p.1960

2023

Volltextzugriff (PDF)

Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100

Cancer epidemiology, biomarkers & prevention, 2016-01, Vol.25 (1), p.98-104

2016

Volltextzugriff (PDF)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

EJHaem, 2024-02, Vol.5 (1), p.105-116

2024

Volltextzugriff (PDF)

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Haematologica (Roma), 2018-11, Vol.103 (11), p.e514

2018

Volltextzugriff (PDF)

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA

HemaSphere, 2023-08, Vol.7 (S3), p.e216416f-n/a

2023

Volltextzugriff (PDF)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

HemaSphere, 2023-11, Vol.7 (11), p.e963-n/a

2023

Volltextzugriff (PDF)

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

The Lancet (British edition), 2023-01, Vol.401 (10373), p.269-280

2023

Volltextzugriff (PDF)

Ropeginterferon Alfa‐2b: Efficacy and Safety in Different Age Groups

HemaSphere, 2020-12, Vol.4 (6), p.e485-n/a

2020

Volltextzugriff (PDF)

A potentially new thromboembolic event scoring system in polycythaemia vera patients: An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia register

European journal of haematology, 2023-08, Vol.111 (2), p.263-270

2023

Volltextzugriff (PDF)

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

Journal of clinical oncology, 2010-10, Vol.28 (30), p.4635-4641

2010

Volltextzugriff (PDF)

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera

Expert opinion on drug metabolism & toxicology, 2021-01, Vol.17 (1), p.3-7

2021

Volltextzugriff (PDF)

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

Blood, 2009-04, Vol.113 (15), p.3435-3442

2009

Volltextzugriff (PDF)

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

International journal of molecular sciences, 2023-03, Vol.24 (6), p.5802

2023

Volltextzugriff (PDF)

1 – 25 von 169

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(146)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(83)
Life Sciences & Biomedicine
(78)
Humans
(68)
Female
(48)
Male
(45)
Aged
(41)
Hematology
(40)
Middle Aged
(40)
Adult
(30)
Oncology
(28)
Aged, 80 And Over
(18)
Patients
(16)
Mutation
(12)
Treatment Outcome
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
General & Internal Medicine
(11)
Medicine, General & Internal
(11)
Survival
(11)
Anemia
(10)
Leukemia
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(44)
Journal Of Clinical Oncology
(14)
Orvosi Hetilap
(14)
Clinical Lymphoma, Myeloma And Leukemia
(11)
European Journal Of Haematology
(6)
Haematologica
(6)
Hemasphere
(5)
The Lancet. Haematology
(5)
Pathology Oncology Research
(4)
The Lancet
(4)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

Fix low dose venetoclax‐azacitidine treatment of unfit acute myeloid leukemia patients

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis

Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Ropeginterferon Alfa‐2b: Efficacy and Safety in Different Age Groups

A potentially new thromboembolic event scoring system in polycythaemia vera patients: An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia register

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

Suchergebnisse filtern